Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Kymera Therapeutics, Inc.

https://www.kymeratx.com/

Latest From Kymera Therapeutics, Inc.

Protein Degradation Leader Nurix Prepares First Clinical Trial

After raising nearly $330m this year, via a financing and IPO, the company is gearing up for a first-in-human trial using its platform technology.

Companies Commercial

Finance Watch: 2020 Is Four Biopharma IPOs Away From Matching 2019

With 46 initial public offerings in the US by drug developers so far – including recent launches by Kymera, Inhibrx and Harmony – 2020 will easily beat last year’s 50 IPOs. In follow-on offerings and VC deals, newly public Schrodinger raised $346.5m and Tango’s $50m equity financing.

Financing Business Strategies

Sanofi Impacted By COVID 19 Headwinds, But Dupixent Powers Forward

Company keeps on track on for 2020 earnings target despite pandemic's hit to general medicines and vaccines sales.

Sales & Earnings Coronavirus COVID-19

Sanofi Nabs Kymera IRAK4 Protein Degrader As It Continues To Build In I&I

Kymera will receive $150m upfront from Sanofi in a deal the big pharma views as an opportunity to develop a breakthrough oral drug for atopic dermatitis and other conditions.

Deals Immune Disorders
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • Kymera Therapeutics, LLC.
UsernamePublicRestriction

Register